

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated polynucleotide ~~comprising~~ consisting of
the a sequence selected from the group consisting of:

(a) ~~sequences provided in SEQ ID NO: 52, 74, 83 and 154;~~

(b) ~~—, the complement thereof, s of the sequences provided in SEQ ID NO: 52, 74, 83 and 154;~~
or a fragment thereof wherein the fragment consists of at least 20 contiguous residues of the
sequence provided in SEQ ID NO: 52, or the complement thereof, and wherein the fragment
detects the presence of the sequence provided in SEQ ID NO: 52, or the complement thereof, in a
biological sample.

(c) ~~sequences consisting of at least 20 contiguous residues of a sequence~~
~~provided in SEQ ID NO: 52, 74, 83 and 154;~~

(d) ~~sequences that hybridize to a sequence provided in SEQ ID NO: 52, 74, 83~~
~~and 154, under moderately stringent conditions;~~

(e) ~~sequences having at least 75% identity to a sequence of SEQ ID NO: 52,~~
~~74, 83 and 154;~~

(f) ~~sequences having at least 90% identity to a sequence of SEQ ID NO: 52,~~
~~74, 83 and 154; and~~

(g) ~~degenerate variants of a sequence provided in SEQ ID NO: 52, 74, 83 and~~
~~154.~~

2. (Canceled)

3. (Original) An expression vector comprising a polynucleotide of claim 1
operably linked to an expression control sequence.

4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.

5.-10. (Canceled)

11. (Previously Presented) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising a polynucleotide according to claim 1.

12.-14. (Canceled)

15. (Currently Amended) A diagnostic kit comprising a polynucleotide at least one oligonucleotide according to claim 8~~1~~.

16.-17. (Canceled)